An app that acts as a conversational feedback mechanism for patients for 12 weeks is being tested by Takeda & Lundbeck to see if it helps depression patients. The study is open to patients on any therapy.
“Our interest here is to improve the wellness of patients, and our medicine is only part of that. We recognize that we can’t do this alone and need to be a partner in the broader healthcare system, particularly in the U.S.,” [Dr. Darryl Sleep, VP and head of Takeda’s U.S. medical office and U.S. medical affairs] said in an interview. “A prescription for an antidepressant to a patient with depression is really not addressing the fundamental problem of depression.”
Other stories from the Fierce network:
- Hospital Impact–Time to put empathy under the microscope
- UnitedHealth adds Samsung, Garmin fitness trackers to wellness program
- Express Scripts rolls out smart inhalers in digital health push
- Blue Cross Blue Shield Association partners with Google affiliate for diabetes care pilot